Minimal Residual Disease Measured after Treatment with Bispecifics in Relapsed Multiple Myeloma: Experience from an Academic Medical Center

被引：0
|
作者：
Blanco, Alberto [1 ]
Chari, Ajai [2 ]
Martin, Thomas G. [2 ]
Arora, Shagun [2 ]
Chung, Alfred [2 ]
Kumar, Anupama Deepa [2 ]
Shah, Nina [2 ]
Wong, Sandy W. [2 ]
Takamatsu, Hiroyuki [3 ]
Martinez-Lopez, Joaquin [1 ]
Wolf, Jeffrey Lee [2 ]
机构：
[1] Hosp Univ 12 Octubre, Dept Hematol, Madrid, Spain
[2] Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA USA
[3] Kanazawa Univ, Dept Hematol, Kanazawa, Japan
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-203768
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7020 / 7021
页数：2
相关论文
共 50 条
  • [1] MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA: A BONE MARROW TRANSPLANTATION CENTER EXPERIENCE
    Ikoma, Maura
    Penitenti, Marcimara
    Marques, Camila
    Mattos, Ederson
    Colturato, Vergilio
    Souza, Mair
    Mauad, Marcos
    Pedro, Andrea
    Cantarelli, Andiara
    Pascolat, Fabricio
    Dameto, Ana
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2011, 80B (06) : 416 - 417
  • [2] Impact of minimal residual disease detection after treatment of multiple myeloma
    Szendrei Tamas
    Plander Mark
    Szabo Zsuzsanna
    Kereskai Laszlo
    Kajtar Bela
    Papp Gergely
    Ivanyi Janos Laszlo
    ORVOSI HETILAP, 2019, 160 (13) : 502 - 508
  • [3] MINIMAL RESIDUAL DISEASE MONITORING IN MULTIPLE MYELOMA PATIENTS BY FLOW CYTOMETRY: A SINGLE CENTER EXPERIENCE
    Sizikova, S.
    Pronkina, N.
    Batorov, E.
    Ushakova, G.
    Sergeevicheva, V.
    Gilevich, A.
    Kruchkova, I.
    HAEMATOLOGICA, 2017, 102 : 789 - 789
  • [4] MINIMAL RESIDUAL DISEASE AFTER BMT FOR MULTIPLE-MYELOMA
    BIRD, JM
    SAMSON, D
    RUSSELL, NH
    BLOOD, 1993, 82 (10) : A199 - A199
  • [5] CARFILZOMIB TREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE
    Uysal, A.
    Ozkan, M. Comert
    Soyer, N. Akad
    Sahin, F.
    Vural, F.
    Tobu, M.
    Tombuloglu, M.
    Saydam, G.
    LEUKEMIA RESEARCH, 2016, 49 : S29 - S30
  • [6] Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Center Experience
    Jimenez-Zepeda, Victor
    Duggan, Peter
    Neri, Paola
    Luider, Joanne
    Tay, Jason
    Bahlis, Nizar J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E67 - E68
  • [7] Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
    Taiga Nishihori
    Jinming Song
    Kenneth H. Shain
    Current Hematologic Malignancy Reports, 2016, 11 : 118 - 126
  • [8] Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
    Nishihori, Taiga
    Song, Jinming
    Shain, Kenneth H.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2016, 11 (02) : 118 - 126
  • [9] Evaluation of Molecular Minimal Residual Disease in Multiple Myeloma: An Institutional Experience
    Hanley, Tim
    Clement, Parker
    Dickey, Laura
    Li, K. David
    MODERN PATHOLOGY, 2018, 31 : 519 - 520
  • [10] Evaluation of Molecular Minimal Residual Disease in Multiple Myeloma: An Institutional Experience
    Hanley, Tim
    Clement, Parker
    Dickey, Laura
    Li, K. David
    LABORATORY INVESTIGATION, 2018, 98 : 519 - 520
12345